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Background: Thrombosis has been associated to some diseases like hyperadrenocorticism (HAC). Several drugs can
alter the balance, such as the corticosteroid prednisone, used mainly for its anti-inflammatory and immunosuppressive
effects. It is known that hypercortisolism can stimulate thrombi formation by increasing coagulation factors and
decreasing fibrinolysis. However it is not known how prednisone administration affects hemostasis in dogs and if it
is dose dependent. The aim of this study, therefore, was to demonstrate the effects of prednisone administration
on dogs’ hemostatic profile.
Results: Significant decrease of antithrombin levels was observed in both groups (anti-inflammatory and
immunosuppressive doses) after 15 days of treatment. An increase of platelet aggregation was observed in dogs
receiving immunosuppressive doses of prednisone (Group II).
Conclusions: From the results obtained in our study, it is not possible to infer that hypercortisolism can increase
the thromboembolic risk, despite the decreased anticoagulant factors (antithrombin levels).
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Despite being more common in humans, thromboembolic
risk has been more associated to hypercortisolism in dogs
than in humans [1]. Prospective studies concerning overall
effects of corticosteroids on hemostasis are rare in dogs. In
human, this risk has been associated to an increase of fac-
tors V, VIII, IX, XI, XII, and prothrombin, von Willebrand
factor, and platelet hyperactivity [2]. Most studies do not
clearly define if hemostatic changes in animals presenting
Cushing’s syndrome are associated to direct effects of corti-
costeroids or secondarily to endogenous elevation observed
in cases of HAC, including those caused by metabolic
imbalances or mineralocorticoid action.
Prednisone is a corticoid widely used in clinics and
veterinary hospital settings. In spite of this fact, only a few
studies have compared the effects of long-term exogenous
administration of prednisone (15 days protocols) at anti-
inflammatory and immunosuppressive doses.* Correspondence: fgazza_vet@hotmail.com
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reproduction in any medium, provided the orTherefore, the aim of this study was to assess the effects
of prednisone on platelet count and function, coagulation
profile and the fibrinolytic system (Table 1) in healthy dogs,




For this study, twenty healthy mongrel neutered dogs, both
sexes (15 females, 5 males), between one and eight years-
old, mean age five years-old, from the university kennel and
from volunteer owners, were used. The normal health sta-
tus was established based on the results of physical exam-
ination, complete blood count, and biochemical profile
(urea, creatinine, ALT, ALP, GGT, glucose, and albumin).
Bitches in estrous, proestrous, pregnant, lactating, and
also obese animals were excluded from the study. Animals
were divided into two groups: Group I, composed of 10
animals, receiving prednisone at anti-inflammatory dose
(1.0 mg/kg/BID PO), for 15 days; Group II, with 10 an-
imals, receiving prednisone at immunosuppressive dose
(2.0 mg/kg/BID PO), for 15 days. Both groups wereLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Medians, p-values and interquartile range (p25; p75) values of hemostatic profile on pre (M0) and
post-treatment (M1) moments of groups I and II
M0 M1 M0 M1
Platelet aggregation (%) 73.00 (71.25;81.5) 81.00 (p = 0.41) (78.03;86) 64.50 (61;86.75) 83.00* (p = 0.03) (77.5;92.25)
Antithrombin (%) 92.3 (87.32;95.05) 76.25* (p = 0.02) (71.48;82.18) 125.25 (106.15;132.15) 77.3* (p = 0.005) (71.67;82.07)
Cortisol (μg/dL) 1.19 (0.97;1.31) 3.28* (p = 0.003) (2.65;7.46) 1.97 (1.38;3.21) 14.97* (p = 0.003) (5.66;21.59)
Factor VIII (%) 110.33 (93.19;171.57) 88.38 (p = 0.36) (60.55;93.19) 161.35 (90.89;243.80) 151.96 (p = 0.77) (135.09;160.36)
Fibrinogen (mg/dL) 234.52 (186.14;234.52) 298.08 (p = 0.30) (158.19;328.21) 234.52 (183.53;348.66) 184.09 (p = 0.09) (162.19;205.77)
vWF (%) 187.58 (148.76;241.42) 111.14* (p = 0.049) (82.9;142.46) 112.21 (100.19;133.48) 79.88 (p = 0.14) (59.09;136.26)
FDP (mg/dL) 0 (0;1) 0 (p = 0.62) (0;2) 1.50 (0.25;2) 1.50 (p = 1.00) (1;2)
Platelets (/μL) 228.000 (204.000;292.500) 226.500 (p = 0.56) (195.250;343.250) 294.500 (217.031;421.000) 348.000 (p = 0.84) (261.750;387.387)
PT (s) 11.80 (11.03;13.05) 10.50 (p = 0.15) (9.7;11.2) 9.90 (9;10.4) 8.50 (p = 0.09) (7.5;9.95)
OMBT (s) 74.50 (59.5;88.75) 86.00 (p = 0.22) (62.25;107.5) 80.00 (55;84.25) 75.50 (p = 0.62) (66.25;100)
TT (s) 14.75 (12.25;17.25) 10.38 (p = 0.07) (9.70;11.40) 11.30 (9.7;12.5) 9.65 (p = 0.18) (9.08;9.98)
aPTT (s) 18.00 (15.75;19.21) 16.00 (p = 0.62) (15.23;18) 14.00 (13.8;14.9) 14.70 (p = 0.64) (13.4;16.23)
vWF: von Willebrand Factor; FDP: Fibrin degradation products; PT: Prothrombin time; OMBT: Oral mucosa bleeding time; TT: Thrombin time; aPTT: Activated Partial
Thromboplastin time. *Statistical difference (p < 0,05).
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hemostatic profile, and urinalysis. These tests were
carried out at day 0 (moment 0) and after treatment
completion (day 15 – moment 1). All performed proce-
dures were previously approved by the Ethics Committee
on Animal Use of the School of Veterinary Medicine and
Animal Science, Univ. Estadual Paulista.
Blood collection
After tricotomy and local antisepsis, blood samples from
the jugular vein were directly collected into vacuum
tubes containing one of the following: EDTA for platelet
and complete blood count; sodium citrate 3.2% in order
to obtain platelet-rich plasma (PRP) for platelet aggrega-
tion test and platelet-poor plasma for the determination
of fibrinogen levels, factor VIII activity, vWF, AT, and FDPs;
no anticoagulant in order to measure cortisol levels. All
blood samples were collected between 8 and 10 AM. At
day 15, blood sample collection coincided with a 2-hour
period after prednisone administration. Platelet-rich plasma
was obtained from samples stored at room temperature
and processed up to two hours after blood sample col-
lection; citrated platelet-poor plasma was obtained from
blood samples kept in ice bath and separated by centri-
fugation up to one hour after blood sample collection.
Samples were immediately frozen in liquid nitrogen and
stored in a freezer at −80°C until processing.
Complete blood count (CBC)
The complete blood count was carried out on an auto-
matic cell counter (model Hemascreen, Ebram Laboratory
Products®), and included red cell count, hemoglobin,
MCV, MCHC, and RDW, total white cell blood count and
platelet count. Platelet count was estimated during bloodsmear evaluation to ensure accuracy of the automated
platelet count. The hematocrit was measured by the
microhematocrit method and plasma protein levels
were determined by refractometry. Differential count
was carried out counting 100 cells on a stained blood
smear (Panótico rápido – Laborclin®).
Platelet aggregation
Platelet aggregation was evaluated by the addition of 50 μL
of ADP (ADP Reagent – Helena Laboratories®) to 400 μL
of PRP (standardized for a 100.000 to 300.000 platelets/
μL count). Platelet response to the agonist was measured
by turbidimetric aggregometry (Netlab 2000 - ZÊNITE®)
and expressed as aggregation percentage.
Oral mucosa bleeding time (OMBT)
The OMBT was evaluated according to Mattoso [3].
Dogs were restrained on sternal or lateral recumbence,
the upper lip was then everted and a standard incision
was made vertically (perpendicular to lip border), directly
under the upper fang, using a lancet (Triplett®). The
chronometer was started immediately after the incision
and blood was absorbed in a circular filter paper located 1
to 2 millimeters away from the incision. The chronometer
was stopped once the bleeding stopped.
Hemostatic profile
The hemostatic profile included determination of factor
VIII activity, fibrinogen levels, PT, aPTT, TT (Helena
Laboratories®), and AT (Siemens®) using commercial kits,
according to recommendations provided by the manufac-
turers. The FDPs were evaluated by latex agglutination test,
according to recommendations provided by the manufac-
turer (Diagnostica Stago®).
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The vWF antigen was measured by direct ELISA method
(ELISA Multiskan EX Original - Labsystems®) using canine
anti-vWF antibody (Sheep anti-canine VWF-Research
Diagnostics Inc®) onto specific plates (Nunc® - Immuno
Plates), according to the technique recommended by the
manufacturer. Control samples were kindly supplied by
Dr. James Catalfamo.
Serum cortisol levels
Serum cortisol levels were measured by radioimmuno-
assay method, using commercial kits for solid-phase
cortisol (Coat – A Count, Siemens®), in order to guar-
antee that significant blood levels of prednisone were
successfully reached.
Statistical analysis
Animals were randomly assigned to one of the two
groups and the results were submitted to the descriptive
analysis laboratory (median and interquartile range). Due
to the presence of variable degrees of asymmetry, the
Wilcoxon test was used to compare the median of each
response variables between study groups moments 0
and 1. For each study group, the Wilcoxon signed rank
test for paired samples was used to make comparisons
between moments [4]. The statistical analysis was made
with PROC NPAR1WAY and PROC UNIVARIATE
(SAS Institute®) procedures.
Results and discussion
Antithrombin (AT) is the major plasma inhibitor among
serine proteases and was the only hemostatic value that
were significantly different in both groups. Its measure-
ment represents the only available test able to assess the
inhibitory factors of coagulation. Healthy dogs present
values greater than 80%; values below 50% are associated to
a greater thromboembolic risk [5]. Antithrombin levels
are significantly decreased after prednisone administration,
which is in accordance to the findings from another study
that found decreased antithrombin levels in animals with
hyperadrenocorticism compared to healthy dogs [6]. This
decrease could have been caused by an impairment on hep-
atic protein synthesis [7]. The median was less than 80% in
both groups and none of the animals showed antithrombin
activity below 50%. On the other hand, Klose et al. did not
show a significant statistical difference comparing healthy
dogs, patients with hyperadrenocorticism, and sick animals
receiving treatment [2].
Although many studies correlate hypercortisolism to
thrombocytosis [8,9], our study did not show a signifi-
cant increase of platelet count after receiving prednis-
one treatment, similar to Klose et al. who studied dogs
with hyperadrenocorticism [2]. The correlation between
increased platelet count and hypercortisolism is extremelycontroversial, as most of the studies aimed to demon-
strate this correlation have evaluated patients with
immune-mediated disorders (e.g., immune-mediated
thrombocytopenia), and consequently, an increase of
platelet number would be expected after corticotherapy
due to a diminution of platelet destruction [10].
The present study did not evidence any significant
difference for OMBT after prednisone therapy in both
groups. This data corroborates the findings of Mackin
et al. who studied healthy dogs, and Eberle and Mischke,
who measured the capillary bleeding time in the toe of dogs
with lymphoma, since they did not find any significant
change on bleeding time when prednisone was used as part
of the chemotherapeutic protocol [11,12]. It is important
to note that OMBT is not a sensitive test to detect minor
changes on platelet function.
In the present study, a significant decrease of von
Willebrand factor (vWF) levels was observed after pred-
nisone administration only on Group I (anti-inflammatory
dose). These findings corroborate those from Giordano
et al. [13], who observed a decrease of vWF antigen levels
after multiple chemotherapy agents, including prednisone,
in children with acute lymphocytic leukemia. Neverthe-
less, these changes could have been caused by other drugs;
in addition, vWF values observed in our study were within
reference range for dogs [14].
It is important to note that the vast majority of the
studies that found increased vWF after corticotherapy,
studied patients who had inflammatory disorders with
concomitant endothelial injury that could explain such
increased values. This can be inferred by the correlation
between vWF levels and C-reactive protein in these
patients; therefore, the decrease of vWF levels could
be explained by prednisone anti-inflammatory effects. It is
not possible to infer why we did not find any significant
decrease associated to immunosupressive dose; moreover,
Jilma et al. observed an important increase of vWF after
the administration of dexamethasone at high-doses to
healthy men [15], although another study has demonstrated
that the increase of VWF levels is not a constant feature of
Cushing syndrome, since some patients may have normal
VWF levels in spite of high circulating cortisol levels. This
fact may be explained because the normal range of VWF
levels is extremely wide since VWF concentrations may be
modulated by several genetic and environmental factors
[16]. Moreover, dexamethasone has a stronger glucocortic-
oid effect than prednisone, which is why these aspects may
explain a more protective role of dexamethasone concern-
ing the development of thrombotic events [7].
A significant increase of platelet aggregation was ob-
served only in the group treated with the immunosup-
pressive dose of prednisone. Thong et al. did not find
any significant change on platelet aggregation in patients
receiving prednisone for two days [17], while Shapiro et al.
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patients treated with a chemotherapeutic protocol con-
taining prednisone [18]. However, it is known that this
protocol include vincristine, which inhibits platelet aggrega-
tion [19], suggesting an antagonistic effect between those
two drugs that could have prevented the prothrombotic
effect of prednisone. Another study evidenced an inhibition
of platelet aggregation in rats receiving variable doses
of dexamethasone for five days [20].
The agonist-induced platelet aggregation, as adenosine
diphosphate (ADP), is an important in vivo indicator of
platelet function. The turbidimetric method used in the
present study has greater clinical relevance and it is eas-
ier to standardize than the electrical impedance method.
Other agonists can be used, such as ristocetin and epineph-
rine, but dogs platelets are much less responsive to these
substances than human platelets; therefore, ADP is the first
choice agonist for platelet aggregation test in dogs [21].
The activated partial thromboplastin time (aPTT) did
not reveal any statistically significant change in both
groups. This fact confirms the findings of another study
that compared this parameter in healthy patients and
individuals with hyperadrenocorticism under treatment
[2]; however it contradicts data from Manetti et al. and
van der Pas et al. both showing shorter aPTT in patients
with hypercortisolism [22,23]. This can be explained
by increased factor VIII activity and fibrinogen levels,
which are important components of the coagulation
cascade [24]. In dogs, aPTT is usually more sensitive to
deficiencies of factors VIII and IX, and it can be prolonged
when there is an activity range of 60 to 75% of these
factors [25]. It is not possible to state that an increase
on these factor activities could lead to a shortened aPTT,
since this test was designed to identify deficiencies on com-
ponents of this coagulation pathway.
Prednisone therapy has been related to increased factor
VIII activity in many studies [8,9,22,23,26-28], a fact that
seems to be correlated to cortisol levels, returning to
normal levels after treatment completion [6]. A decreased
factor VIII activity was noted in both groups, although no
significant difference was observed, confirming the data
reported by Jacoby et al. in dogs, and in humans by other
authors [6,29].
The present study did not evidence any significant dif-
ference (p < 0,05) on PT values after treatment comple-
tion in both groups, confirming the data reported by
Klose et al. [2], which could be explained by the fact that
this test is closely related to fibrinogen levels and factor
VII, V, and X activities (common and intrinsic pathways
of coagulation) [24]. However, fibrinogen levels were not
significantly different in both groups after administration
of prednisone. The other coagulation factors cited were
not evaluated in our study, preventing a complete relation
between PT and these factors.The thrombin time (TT) assesses the common pathway
of coagulation; therefore, it is an indirect test of plasma
fibrinogen levels [24]. It is not widely used in studies
involving hypercoagulability and administration of cor-
ticosteroids, probably because most of these studies
preferred to evaluate fibrinogen levels in order to assess
this pathway. There was no statistical difference in TT
after treatment completion in both groups.
Fibrinogen levels were not significantly different after
treatment completion when compared to the control
moment in both groups. This fact supports the results
obtained by Klose et al. [2]. Other authors confirmed
an increase of fibrinogen levels, but most of them eval-
uated the hemostatic profile on patients with hypera-
drenocorticism [6,22,23,26,30]; nevertheless, Giordano
et al. found a significant decrease of plasma fibrinogen
levels [13] confirming the findings of other study [31].
These studies suggest liver dysfunction caused by pred-
nisone administration, leading to a decrease of hepatic
fibrinogen synthesis.
There were no significant changes regarding FDPs values
between different moments. This data confirms the
findings of a study that evaluated patients treated with
a chemotherapeutic protocol containing prednisone [27].
The hypercoagulable condition evidenced by decreased
levels of antithrombin does not seem to have led to a
thrombotic event.
The hypercoagulability should not be explained only
by the increased procoagulant factors, but also by the in-
hibition of the fibrinolytic system and decreased anti-
thrombin activity [6]. It is extremely difficult to correlate
hypercortisolism to thromboembolism in dogs, since the
studies that evaluated these effects are vastly based on
data from human studies. There are other factors involved
in the thromboembolic risk than just increased procoagu-
lant factors and decreased fibrinolytic factors, such as
systemic arterial hypertension, a more prominent sign
in human beings with hyperadrenocorticism than in
dogs suffering from the same condition. The thromboe-
lastography (TEG) is a reliable method to define the in-
crease of thromboembolic risk, especially due to the use
of whole blood samples, thus including the contribution
of cellular components on hemostasis, when compared
to tests using citrated plasma [2]. Meanwhile, the tests
carried out in this study have advantages over TEG because
it details which elements are involved on the possibility
of increased thromboembolic risk, a fact that cannot be
studied and detailed by using TEG.
In human, the hypercoagulable condition has been
associated to hyperadrenocorticism due to an increase
of factor VIII activity, or to associated increased factors
VIII, V, and prothrombin, or by increased von Willebrand
factor and factors VIII, IX, XI, and XII, and platelet
hyperactivity [2]. Many authors have tried to correlate
Romão et al. BMC Veterinary Research 2013, 9:268 Page 5 of 6
http://www.biomedcentral.com/1746-6148/9/268thromboembolism associated to hyperadrenocorticism
with increased procoagulant factors and diminished fi-
brinolytic system in dogs [2,6]. Studies where authors have
tried to confirm the correlation between thromboembol-
ism and hypercortisolism have not evaluated the possibil-
ity of concurrent morbid processes [32,33], which are very
common findings in human beings affected by hyperadre-
nocorticism, such as insulin resistance and systemic arter-
ial hypertension [2].
The chronic corticotherapy is a well-known risk factor
for thrombosis in dogs, since a 7-day prednisone protocol
at 1.0 mg/kg/day resulted in thromboelastographic changes
in healthy dogs. Although it is impossible to determine
if prednisone administration is the only cause, it is rea-
sonable to conclude that glucocorticoids may contribute
to a hypercoagulable condition [34]. A study made by
Rose et al. proved the hypercoagulable condition using
both anti-inflammatory and immunosuppressive doses in
dogs treated for two weeks with prednisone, which was
confirmed by thromboelastographic changes [10].
The lack of statistical difference in the parameters be-
tween anti-inflammatory and immunosuppressive doses,
observed by Rose et al. [10] and the present study, suggests
that there is no dose-dependent effect of prednisone on the
hemostatic system in a two-week protocol.
Conclusions
It is not possible to infer that prednisone administration
does not cause a thromboembolic risk in dogs, since the
decrease in antithrombin levels with anti-inflammatory
and immunosuppressive doses did not reach clinical
significant levels. There is no evidence of prednisone
dose-dependent activity on hemostasis. Although thrombo-
embolic risk was not associated to exogenous hypercor-
tisolism in healthy dogs, the occurrence of other
systemic conditions should be taken into consideration
on corticotherapy.
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